All In Biotech

Drug Trial Radar · NCT06651281

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

A Phase 3 Extension Study to Evaluate the Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,380

Planned (sponsor's estimate)

Start

Nov 25, 2024

Primary completion

Dec 17, 2037

Study completion Dec 17, 2037

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers want to learn more about tulisokibart (also known as MK-7240) in an extension study. Tulisokibart is a medicine designed to treat active, moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). An extension study is a type of study where people who received tulisokibart in certain other studies for CD or UC (called a parent study) may be able to join this study. The goals of this study are to learn about the safety of tulisokibart over time in people with CD or UC, and if people tolerate it.

Conditions

  • Crohn Disease
  • Colitis, Ulcerative

Interventions

  • TulisokibartDrug

    Humanized monoclonal antibody that binds human tumor necrosis factor-like cytokine 1A (TL1A), administered subcutaneously

  • Placebo to tulisokibartDrug

    Placebo matching SC tulisokibart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 378 weeks
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 364 weeks

Locations

37 sites in 7 countries. Site status is shown where the registry gives one.

  • Connecticut Clinical Research Institute ( Site 0297)

    Bristol, Connecticut · Recruiting

  • St. Joseph Mercy Hospital - Huron Gastroenterology Associates ( Site 0287)

    Ypsilanti, Michigan · Recruiting

  • BVL Research - Kansas ( Site 0292)

    Liberty, Missouri · Recruiting

  • New York Gastroenterology Associates ( Site 0253)

    New York, New York · Recruiting

  • GI Alliance - Digestive Health Associates of Texas - DHAT ( Site 0290)

    Garland, Texas · Recruiting

  • GI Alliance - Lubbock ( Site 0288)

    Lubbock, Texas · Recruiting

  • Caprock Gastro Research ( Site 0293)

    Lubbock, Texas · Recruiting

  • Southern Star Research Institute ( Site 0299)

    San Antonio, Texas · Recruiting

  • GI Alliance - Southlake ( Site 0298)

    Southlake, Texas · Recruiting

  • Tyler Research Institute ( Site 0294)

    Tyler, Texas · Recruiting

  • University of Virginia Health System ( Site 0291)

    Charlottesville, Virginia · Recruiting

  • Washington Gastroenterology - Tacoma ( Site 0295)

    Tacoma, Washington · Recruiting

  • Hepato-Gastroenterologie HK ( Site 0700)

    Hradec Králové, Czechia · Recruiting

  • Vojenská Nemocnice Brno-Internal department ( Site 0701)

    Brno, Brno-mesto, Czechia · Recruiting

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 1002)

    Nice, Alpes-Maritimes, France · Recruiting

  • CMC Ambroise Paré Hartmann - Institut des MICI ( Site 1003)

    Neuilly-sur-Seine, Hauts-de-Seine, France · Recruiting

  • CHRU De Nancy - Hopital de Brabois ( Site 1001)

    Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France · Recruiting

  • Hopital Claude Huriez CHRU LILLE ( Site 1004)

    Lille, Nord, France · Recruiting

  • ARENSIA Exploratory Medicine Georgia ( Site 1104)

    Tbilisi, Georgia · Recruiting

  • Semmelweis Egyetem ( Site 1400)

    Budapest, Hungary · Recruiting

  • Békés Megyei Központi Kórház Dr. Réthy Pál Tagkórház-4. Belgyogyaszat Gasztroenterologia ( Site 1411)

    Békéscsaba, Bekes County, Hungary · Recruiting

  • Rivermed Sp. z.o.o. ( Site 2206)

    Poznan, Greater Poland Voivodeship, Poland · Recruiting

  • Centrum Diagnostyczno - Lecznicze Barska sp. z o.o. ( Site 2208)

    Włocławek, Kuyavian-Pomeranian Voivodeship, Poland · Recruiting

  • Krakowskie Centrum Medyczne ( Site 2210)

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • Bonifraterskie Centrum Medyczne ( Site 2207)

    Lodz, Łódź Voivodeship, Poland · Recruiting

  • Centrum Medyczne Oporow ( Site 2212)

    Wroclaw, Lower Silesian Voivodeship, Poland · Recruiting

  • Melita Medical Sp. z o.o. ( Site 2204)

    Wroclaw, Lower Silesian Voivodeship, Poland · Active not recruiting

  • Przychodnia Futuremeds Wroclaw ( Site 2211)

    Wroclaw, Lower Silesian Voivodeship, Poland · Active not recruiting

  • 1 Wojskowy Szpital Kliniczny Z Poliklinika SPZOZ w Lublinie ( Site 2205)

    Lublin, Lublin Voivodeship, Poland · Recruiting

  • Medrise Sp. z o.o. ( Site 2200)

    Lublin, Lublin Voivodeship, Poland · Recruiting

  • EB Group Sp. Z o.o. Centrum Zdrowia MDM ( Site 2202)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Vivamed Sp. z o.o. ( Site 2201)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • WIP Warsaw IBD Point Professor Kierkus ( Site 2209)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

  • Vita Longa Sp. Zoo ( Site 2213)

    Katowice, Silesian Voivodeship, Poland · Recruiting

  • Sonomed Sp. z o. o. ( Site 2203)

    Szczecin, West Pomeranian Voivodeship, Poland · Recruiting

  • MAC Research - Merseyside ( Site 3401)

    Prescot, Knowsley, United Kingdom · Recruiting

  • Whipps Cross University Hospital ( Site 3400)

    London, Waltham Forest, United Kingdom · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.